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INTRODUCTION 
Quinidine is a naturally occurring substance used in the treatment 
of cardiac arrhythmias. It may be administered orally or parenterally 
to control both ventricular and supraventricular arrhythmias. Because 
of its low therapeutic index, it is rational to obtain plasma concen-
trations of quinidine as a guide to the safest and most effective dose. 
Unfortunately, past studies that were designed to compare plasma 
quinidine concentration to arrhythmias control and electrocardiographic 
(ECG) changes used nonspecific assay techniques."'' ^  Such methods can 
neither completely nor consistently separate quinidine from its meta-
bolites and contaminants which may differ in their myocardial and 
possibly their toxic effects. Our experience has been that arrhythmia 
control can often be achieved with plasma quinidine concentrations lower 
than the reported therapeutic ranges. The availability of a high per-
formance liquid chromatography (HPLC) method provides an opportunity 
to establish a more accurate therapeutic range using a highly specific 
assay technique. This has not been adequately studied although it is 
suggested that therapeutic efficacy may be achieved at a concentration 
8 9 of 1.0 or 0.7 mcg/ml. 
Investigators have evaluated the effects of quinidine on intraven-
4 6 
tricular conduction and ventricular repolarization. ' In 1970, 
Heissenbuttel et al,4 employed the nonspecific fluoroiaetric assay 
described by Brodie and Udenfriend to determine the plasma quinidine 
concentration in 20 patients started on oral quinidine and monitored 
2 
for three days. Within the range of 2 to 5 meg/ml, quinidine caused a 
significant increase in the duration of the QRS complex and the QT in-
terval on the electrocardiogram. Furthermore, widening of the QRS com-
plex was directly proportional to increases in the plasma quinidine 
concentration. A recent study by Holford et al,6 examined the relation-
ships between electrocardiographic readings, systolic time interval 
measurements and changes in the plasma quinidine concentration. The 
plasma concentrations were determined in 10 normal subjects. The major 
effect of quinidine was slowing of cardiac repolarization; this was 
supported by their observation of prolongated QT intervals. Holford 
6 
et al, noted small increases in the PQ interval and the QRS complex. 
To date, there are no published reports comparing quinidine concen-
trations assayed by the specific HPLC assay with concurrent ECG changes 
in patients requiring chronic antiarrhythmic therapy. 
This study examined the relationship between HPLC-derived plasma 
quinidine concentrations, arrhythmia control and simultaneous six lead 
ECG measurements in patients requiring antiarrhythmic therapy. 
Study Objectives 
1. Evaluate the correlation between the independent variable (plasma 
quinidine concentration) and the dependent variables (changes in the 
QRS complex and the QT interval) and determine if these electrocardio-
graphic measurements can be used as reliable predictors of the patients' 
plasma quinidine concentration. 
2. Determine if the changes in the QRS complex and the QT interval 
occur at the same quinidine concentration or if the changes in one ECG 
parameter occur at a lower quinidine concentration than the changes in 
the other. 
3 
3. Evaluate differences between responders and nonresponders to quini 
dine therapy by comparing the mean plasma concentration, mean changes 
in the ECG parameters in the two groups. Therapeutic response was 
determined at steady state quinidine concentrations. 
MATERIALS AND METHODS 
Patient Selection 
Inclusion Criteria: Patients, 18 years of age or older, who 
required antiarrhythmic therapy and have signed an informed consent 
were admitted to the study. Patients were located at the University 
Hospital Coronary Intensive Care Unit or 4 North Telemetry Unit. 
Exclusion Criteria: A patient was excluded from the study If at 
the start of the study or throughout the course of the study the 
patient met any of the following criteria: 
1. Hypersensitivity reaction to quinidine, quinine, or other cinchona 
alkaloids. 
2. Side effects experienced by the patient which in the opinion of 
the attending physician warranted discontinuation of the drug, e.g., 
gastrointestinal intolerance, tinnitus, hemolytic anemia. 
3. Concomitant use of any of the following antiarrhythmic agents 
(procainamide, disopyramide, phenytoin, and verapamil). This included 
any period of time less than 5 half-lives between discontinuation of 
the agent and the start of quinidine therapy. 
4. Concomitant use of tricyclic antidepressants, ph enothiazxnes, or 
other psychotherapeutic agents excluding the benzodiazepine derivatives 
5. Serum potassium concentrations that continually vary from the 
normal range (3.5-5.0 mEq/L). 
6. Pregnancy determined by the patient's history. 
4 
7. Concomitant use of any of the following hepatic microsomal enzyme 
inducing agents: barbiturates, phenytoin, rifampin, griseofulvin, or 
glutethimide within four weeks of starting quinidine therapy. 
Electrocardiographic Measurements 
All ECG measurements in this study were obtained from a standard 
six-lead (I, II, III, AVR, AVL, and AVF) electrocardiogram recorded on 
a Hewlett-Packard 1515 B Automatic Cardiograph at a paper speed of 
50 mm/sec. All ECG tracings were performed with the patients in the 
supine position. The ECG lead yielding the widest QRS complex was used 
to measure the QRS complex for that ECG tracing. Five separate 
measurements were obtained from each tracing by the same two cardiology 
residents who were unaware of the patients' plasma quinidine concen-
trations. The ten observations were averaged. The same procedure was 
10 
repeated for the QT interval determinations. Bazzett's formula 
(QT = Q •) was used to correct the QT interval for heart rate. 
The accuracy in measurement of the QRS complex and QT interval was 
± 5 m-sec. 
Before the start of quinidine therapy, a baseline six-lead ECG 
was obtained fr OIT1 3.11 patients entered in the study. This served as 
the control value for QRS and QT interval determinations. 
In order to evaluate therapeutic response on the criteria set 
forth by this protocol, all patients enrolled in the study had constant 





Patients received a maintenance dose of 10-14 mg/kg/day of quini-
dine base administered orally as the sulfate or the gluconate salt as 
divided doses at six to eight hour intervals. 
Blood Sampling Techniques 
Peak blood samples (drawn two hours after the oral dose of quini-
dine sulfate and four hours after the oral dose of quinidine gluconate) 
and simultaneous six-lead ICG measurements were obtained twice on day 
one and two, and once on the third day after the start of quinidine 
therapy. 
The blood samples were drawn through an intravenous heparxnized 
catheter. The initial 2 ml of blood were discarded and 7 ml of blood 
were collected in a collection tube containing sodium fluoride and 
potassium oxalate. The samples were centrifuged immediately and the 
plasma was frozen in silanized teflon cap, screw-type culture tubes. 
Analytical Method^ 
Plasma quinidine determinations were performed in the Clinical 
Toxicology Laboratory of the University of Utah Hospital. The assay 
7 
employed was the HPLC method described by Bridges et al for simul-
taneous quantitation of quinidine, procainamide, N-acetylprocainamide, 
and disopyramide. This assay had a sensitivity limit of 0.5 mcg/ml 
and a coefficient of variation for identical samples of less than four 
percent. 
6 
11 Data Analysis 
The relationship between the changes in the QRS complex and the QT 
interval from control values (A QRS and A QT) and the plasma quinidine 
concentration (mcg/ml) was plotted on a scattergram. A least squares 
line of best fit obtained. Linear regression analysis was used to 
determine if electrocardi ographic measurements could be used as re-
liable predictors for plasma quinidine concentration. 
Student's t-test was used to evaluate the difference between the 
mean plasma concentration required to produce greatest change from 
baseline for each of the ECG parameters. 
A patient was deemed a responder if either or both of the fol-
n . 12 lowing criteria were met: 
1. conversion to normal sinus rhythm after the start of quinidine 
therapy in patients with atrial fibrillation or atrial flutter 
2. complete suppression of ventricular premature beats (VPB) for 
one-half hour, or 90 percent suppression for at least two consecutive 
half-hour segments of the dosing interval in patients with ventricular 
dysrhythmias when compared to baseline. 
RESULTS 
Preliminary data were obtained from four patients who 
completed the study. All four patients met all criteria set forth by 
the protocol. The mean age of the patients was 71 years (Table I). 
The four subjects had a normal baseline CBC, platelets, arterial blood 
gases, and serum potassium measurements, 
A total of 17 simultaneous six-lead electrocardiograms and blood 
samples were obtained from the four patients (Table II). The change 
7 
in the QRS complex (A QRS) and the change in the rate-corrected QT 
interval (A QTc) were plotted as a function of the plasma quinidine 
concentration (Figures A and B). The Pearson product moment cor-
relation coefficient showed a linear relationship (p < 0.01) between 
the changes in the dependent variables and the plasma quinidine 
concentration. The slope of the regression line for each graph is 
significantly different from zero (p < 0,01). 
Table III lists the control values and the maximum values for the 
QRS complex and the QT^ interval for the study group. Eight percent 
and four percent change from baseline were considered significant 
changes (p < 0.05) for the QRS complex and QT£ interval, respectively. 
There was a significant difference between control value and maximum 
recorded EGG parameter reading for each patient (p < 0.05). 
Table IV lists the plasma concentrations that produced the greatest 
change from baseline for each of the EGG parameters. There was no sig-
nificant difference (p > 0.05) between the plasma concentration yielding 
the greatest change in the QRS complex and QT^ interval for the sample. 
Two of the four patients (patients 1 and 4) responded to quinidine 
therapy. Patient one suffered from a recent onset of frequent multi-
focal premature ventricular depolarizations and coarse citi 1TX3.!!. fxbxrxl**" 
lation with a rapid ventricular response. The patient was started on 
quinidine and digoxin resulting in conversion to normal sinus rhythm. 
A 24 hour Holter recording obtained before discharge was compared to the 
pretreatment 24 hour Holter recording; a marked reduction in the fre-
quency and the complexity of ventricular arrhythmias was noted. The 
average estimated premature ventricular depolarization had been reduced 
8 
from 20 per hour to 16 per hour. Couplets were rare, and triplets and 
four-heat runs of ventricular tachycardia had been abolished. The 
patient did not report any quinidine side effects. 
Patient four had a history of heart failure for which she was being 
treated with digoxin and furosemide; the patient was admitted to 
University Hospital when she developed atrial fibrillation with a 
rapid ventricular response. The patient was placed on quinidine and 
converted to normal sinus rhythm within 24 hours after the start of 
quinidine therapy and has remained in normal sinus rhythm. 
Patients two and three failed to respond to quinidine therapy. 
Both subjects suffered from frequent complex premature ventricular 
beats which based on 24 hour Holt er monitoring did not 
decrease from baseline after quinidine therapy which produced serum 
concentrations within the range of 2-5 meg/ml. These patients were 
unable to tolerate higher doses of quinidine due to gastrointestinal 
disturbances caused by the drug. 
Only minimal differences were found in the mean plasma, 
quinidine concentration or the mean changes in the electrocardiographic 
parameters between responders and nonresponders, Tables V, VI, VII. 
DISCUSSION 
In man, the most prominent electrocardiographic effect of quini-
dine at therapeutic plasma concentrations appears to be prolongation 
13 
of the QT interval without widening of the QRS complex. ' Anti-
arrhythmic effects of quinidine have been reported when QT prolongation 
15 
occurred without notable effects on the duration of the QRS complex. 
Widening of the QRS complex has been considered a late effect seen when 
13 high plasma concentrations of quinidine are achieved. Heissenbuttel 
4 
and Bigger, suggested that failure to recognize QRS widening at low 
quinidine concentrations might be due to an inability to recognize the 
small changes that occur in the width of the QRS complex when measured 
on the standard electrocardiographic tracing sensitive only to ± 20 m-
sec. By using an oscilloscopic time expanded display to enhance hori-
zontal amplification of the ICG parameter, these authors found that 
quinidine significantly prolonged the duration of the QRS complex at 
serum concentrations as low as 2 mcg/ml. Significant changes in both 
the QRS complex and the rate-corrected QT interval correlated with 
plasma quinidine determinations within the range of 2-5 mcg/ml deter-
4 mined by the method of Brodie and Udenfriend. More recently, Hoi ford g 
et al administered single doses of quinidine to ten normal volunteers 
and correlated the changes in the QRS complex and the rate-corrected 
QT interval with plasma quinidine concentrations determined by HPLC 
assay. Using standard electrocardiographic techniques, these researchers 
found a significant correlation between the QT interval and plasma 
concentration within the range of 1-3 mcg/ml while no correlation was 
found between the QRS complex and plasma concentration. 
There are no published reports comparing quinidine concentrations 
determined by the HPLC assay with concurrent electrocardiographic 
changes in patients requiring chronic antiarrhythmic therapy. This 
study examined the relationship between HPLC-derived plasma quinidine 
concentrations, arrhythmia control and simultaneous six-lead electro-
cardiographic measurements in patients requiring quinidine therapy, to 
10 
determine therapeutic range for quinidine and to devise a non-invasive 
monitoring technique for quinidine therapy. 
The linear regression analysis revealed a significant correlation 
between the ECG parameters and the plasma quinidine concentration for 
the patients in this study. The slope of the regression line demon-
strated that the dependent variables change as a function of the 
quinidine concentration within the range of 1.1-4.8 mcg/ml. These 
4 
results are consistent with the findings of Heissenbuttel and Bigger, 
and may reflect the more precise electrocardiographic method used. The 
heightened sensitivity of measurement (± 5 m-sec) allowed for the 
detection of 8-43 m-sec changes in the ECG measurements. It should be 
emphasized that the greater accuracy of measurement was achieved by 
doubling the speed of the ECG recording to enhance the horizontal 
amplification of the QRS complex and QT interval and by using an ECG 
caliper rule to perform the measurements. This technique is feasible 
in most hospitals and clinics in the United S t cl t GS» 
The lower range of plasma concentrations reported in this study 
4 13 14 
compared to reports of other similar studies can be explained 
by the difference in the assay used. The nonspecific assays used by 
previous researchers cannot adequately separate quinidine from its 
impurity and its polar metabolites. A 20-50 percent increase in con-
centration above the "true" quinidine concentration has been reported 
1 
when nonspecific assays are compared to HPLC quinidine determinations. 
The utility of the QRS complex and the rate-corrected QT interval 
in assessing therapeutic response and potential toxicity deserves 
further examination. In this study, a 64 percent widening of the QRS 
complex was seen in patient two at a serum concentration of 2.8 mcg/ml; 
I H 9 S B H S B I 
11 
a quinidine concentration of 4.5 mcg/ml produced a 54 percent change in 
the QRS complex in patient one. Visual inspection of the 95 percent 
confidence interval in Figures A and B readily discloses the wide range 
of values in the ECG measurements corresponding to a given quinidine 
concentration. These findings contradict those previously reported 
13-15 
in the literature. This may be due to the small number of 
subjects in this report. 
15 
Lyon and DeGraff have postulated that the antiarrhythmic ef-
fects of quinidine are seen when QT prolongation occurs without notable 
effects on the duration of the QRS complex. Based on this statement 
one would expect that the maximum prolongation of the rate-controlled 
QT interval would occur at a lower quinidine concentration when com-
pared to maximum widening of the QRS complex. However, in this study, 
no significant difference (p > 0.05) was found between the plasma con-
centration causing the greatest degree of change in each of the ECG 
parameters. Once again, these findings are consistent with the data 
by Heissenbuttel and Bigger and may reflect the similar method employed 
in measuring ECG changes. 
Assessing antiarrhythmic response is controversial'because there 
is marked spontaneous variability in the incidence of ectopic activity 
1. 1 7 
from one hour to the next, from one 24 hour Holter monitor to another. 
Furthermore, there appears to be an even greater spontaneous variability 
in ventricular premature beat complexity than in the frequency of these . • k . 10 ectopic beats. 
Based on the stringent criteria for therapeutic response used in 
this study, there was a 50 percent response rate within the range of 
0.75-6.6 mcg/ml of quinidine in plasma, but no differences were 
observed between responders and non-responders when plasma quinidine 
concentration, QRS complex widening, and prolongation of the rate-
corrected QT interval were compared. Similar results have been ob-
served by other investigators (Ueda CT, personal communication) who 
have tried to discern differences in the plasma concentrations between 
responders and non-responders to quinidine therapy. These findings 
raise the question of whether response occurred as the result of the 
added antiarrhythmic effects of the polar metabolites of quinidine. 
18 
Drayer et al have demonstrated that quinidine, 3-hydroxyquinidine 
(3-OH) and 2'-oxoquinidinone (2'-0X0) were equally potent antiar-
rhythmic drugs when tested against chloroform and hypoxia-induced 
ventricular fibrillation in mice. They also found large interpatient 
variation in the plasma concentration of the 3-OH and 2'-0X0 metabo-
lites in patients on long term quinidine therapy. It is possible 
that the metabolites accumulate in some patients and contribute to 
18 
the antiarrhythmic effect of quinidine. 
To date no study has focused on the antiarrhythmic activity of 
quinidine metabolites in man, A study comparing the concentration of 
quinidine and its metabolites in plasma of patients with therapeutic 
response versus patients who fail to respond or develop quinidine 
toxicity would seem warranted. 
CONCLUSION 
The data evaluated in this study were obtained from only four 
patients. The few patients reflect the strict criteria required if 
this type of study is to be valid. Adding to the problem of small 
sample size was the apparently large interpatient variability in 
13 
electrocardiographic changes measured in this study. Even though some 
of our findings are consistent with previous reports and various 
observations are statistically significant, these data should be 
interpreted as trends and should not be extrapolated to the general 
population. A study to confirm our findings in a larger number of 
patients and to evaluate the antiarrhythmic activity of the metabolites 
of quinidine is indicated. 
TABLES 
15 
Table I. Age of Study Subjects, Type of Arrhythmias Treated 
and Baseline Values for the ECG Parameters 





QRS ± S.D. 
(Msec) 
Baseline 





1 66 PVC 79 ± 4.2 400 ± 5.6 Yes 
2 80 PVC 62 ± 4.5 436 ± 8.9 No 
3 67 PVC 106 ± 8.9 396 ± 25.0 No 
4 70 Atrial Fib 61 ± 2.2 412 ± 6.8 Yes 
Mean 
(± S.D.) 
71 77 + 23.51 411 ± 18 
The mean value for the population's age and baseline ECG values are 
listed on the bottom row. The response column indicates the outcome 
of quinidine therapy based on the criteria stated in the protocol. 
16 
Table II. ECG Recordings and Plasma Quinidine Determinations From 
the Four Subjects 
Patient Sample Cp Quinidine X QRS+SD A QRS X QTC±SD A QTC 
No, No. (meg/ml) (Msec) (Msec) (Msec) (Msec) 
1 1 4.50 122 ± 2.7 43 566 ± 5.6 166 
1 2 3.50 97 + 4.5 18 461 ± 2.9 61 
1 3 6.60 119 + 2.2 40 450 ± 3.2 50 
1 4 3.20 120 ± 3.5 41 501 ± 2.7 101 
1 5 4.80 108 + 2.7 29 530 ± 5.2 130 
1 6 4.05 111 ± 5.5 32 549 ± 2.6 149 
2 7 1.30 72 ± 7.6 10 462 + 7.2 26 
2 8 1.10 93 + 7.6 31 499 ± 1.1 63 
2 9 1.40 94 + 4.2 32 441 + 1.0 5 
2 10 3.00 91 + 6.5 29 474 ± 1.0 38 
2 11 2.80 102 + 1,0 40 491 ± 5.3 55 
3 12 1.60 110 + 14.0 4 410 ± 5.6 14 
3 13 1.80 114 + 11.0 8 412 ± 8.0 16 
3 14 2.85 136 + 4.0 30 442 ± 8.3 46 
4 15 0.75 70 + 3.5 9 428 + 8.4 16 
4 16 2.00 71 + 2.2 10 420 + 3,9 8 
4 17 2.30 83 + 2.7 22 430 ±3.2 18 
17 
Table III. Control Values and the Maximum Values for the QRS Complex 
and QT Interval for Each Patient c 
Control Maximum Control Maximum 
Patient QRS ± S.D. QRS QTC QTC No. (Msec) (Msec) (Msec) (Msec) 
1 79 + 4.2 122 ± 2.7 400 ± 5.6 566 ± 5.6 
2 62 ± 4.5 102 ± 1.0 436 ± 8,9 499 ± 1.1 
3 106 ±8.9 136 ±4.0 396 + 25.0 442 + 8.3 
4 61 + 2.2 83 ± 2.7 412 ± 6.8 430 ±3.2 
18 
Table IV. Plasma Concentration at the Time of Greatest Change from 
Baseline for Each of the ECG Parameters are Listed for 
Each Patient 
Maximum 
Patient CP Quinidine Maximum Change Cp Quinidine Change 
No. (meg/ml) QRS (Msec) (meg/ml) QTC (Msec) 
1 4.50 43 4.50 166 
2 2.80 40 1.10 63 
3 2.85 30 2.85 46 
4 2.30 22 2.30 18 
19 
Table V. Comparison of Mean Plasma Concentration Between Responders 
and Non-Responders to Quinidine Therapy 
Responders 
(Patient No.) 




X Cp Quinidine 
(mcg/ml) 
1 4.44 2 1.92 
4 1.68 3 2.08 
X 3.06 2.00 
S.D. 1.95 0.115 
20 
Table VI. Comparison of Mean Changes in the QRS Complex Between 
Responders and Non-Responders to Quinidine Therapy 
Responders Mean Change Non-Responders Mean Change 
(Patient No.) QRS (Msec) (Patient No •) QRS (Msec) 
1 38.83 2 28.40 








Table VII. Comparison of Mean Changes in the QT£ Interval Between 
Responders and Non-Responders to Quinidine Therapy 
Responders Mean Change Non-Responders Mean Change 
(Patient No.) QTC (Msec) (Patient No.) QTC (Msec) 
1 109.50 2 33.40 









Figure A. Relationship Between Change in QRS Duration From 
Control Values in Milliseconds (A QRS) and Plasma 
Quinidine Concentration in mcg/ml for the Study 
Sample 
Cp QUINIDINE (mcg/ml) 
The calculated regression- line and the 95 percent prediction 
interval (broken line) are shown. The change in QRS duration 
noted in the measurement is dependent on plasma quinidine concen-
tration (slope =» 5.179, p < 0.01) 
24 
Figure B. Relationship Between Change in Rate-Corrected QT Interval From 
Control Values in Milliseconds (AQTC) and Plasma Quinidine Concentration 
Cp QUINIDINE (meg/ml ) 
The calculated regression line and the 95 percent prediction interval 
(broken line) are shown. The change in the QTC interval noted in these 
measurements is dependent on plasma quinidine concentration (slope = 
20.41 p < 0.01) 
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Graduate Certificate in Gerontology 
University of Utah, Salt Lake City, UT 
January 1982-June 1983 
Bachelor of Science - Pharmacy (Cum Laude) 
Philadelphia College of Pharmacy and Science, Philadelphia, 
August 1977-January 1981 
Biology Major 
Ursinus College, Collegeville, PA 
September 1976-May 1977 
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EDUCATION AND TRAINING (continued) 
Doctor of Pharmacy 
Clinical Rotations: Adult Internal Medicine 
General Surgery 
Adult Cardiology 











Hospital Pharmacy Management 
Poison Control Center 
Medical Intensive Care - Coronary 
Care 
HONORS 
The Grace P. Swinyard Memorial Scholarship for Scholastic 
Achievement, University of Utah, College of Pharmacy, 1982 
The Smith Kline and French Laboratory Award for Superior 
Achievement in Clinical Pharmacy, Philadelphia College of 
Pharmacy and Science, 1981 
Rho Chi Pharmaceutical Honor Society, Alpha Tau Chapter, 1980 
National Association of Chain Drug Stores Pharmacy Education 
Foundation Scholarship, Philadelphia College of Pharmacy and 
Science, 1980 
TEACHING EXPERIENCE 
"Arrhythmias" Clinical Pharmacy 539 - Diseases and Drug Therapy, 
Winter Quarter 1983 
"Treatment of Arrhythmias" Clinical Pharmacy 539 - Diseases and 
Drug Therapy, Winter Quarter, 1983 
"Treatment of Hypertension in the Elderly" Clinical Pharmacy 520 -
Drug Use in the Elderly, Winter Quarter 1983 
"Mock Cardiac Arrest Workshop" Pam Cipriano, R.N., Adult Intensive 
Care Clinical Specialist, Edgar Gonzalez, Clinical Pharmacy Resi-
dent. CPR Quality Assurance Program, Department of Nursing, 



















TEACHING EXPERIENCE (continued) 
"Myocardial Electrophysiology and Antiarrhythmic Agents" Clinical 
Pharmacy 610 - Advanced Pharmacotherapeutics, Fall Quarter 1982 
Teaching Fellow - Department of Pharmacy Practice, University of 
Utah, College of Pharmacy, Clinical Pharmacy 605 - Applied 
Clinical Pharmacokinetics, Summer Quarter 1982. Responsibilities: 
select reading assignments, formulate work problems, conduct 
weekly problem and review sessions 
"The Pharmacokinetics of Vancomycin" Clinical Pharmacy 605 -
Applied Clinical Pharmacokinetics, Summer Quarter 1982 
"The Pharmacokinetics of Disopyramide" Clinical Pharmacy 605 -
Applied Clinical Pharmacokinetics, Summer Quarter 1982 
Teaching Fellow - Adult Medicine, Drug Information, Pediatrics, 
and General Surgery Clerkships, Department of Pharmacy Practice, 
University of Utah College of Pharmacy, Winter Quarter 1982-Fall 
Quarter 1981. Responsibilities: teach skills in patient 
monitoring, drug therapy selection, medication histories, and 
conduct pharmacy rounds 
PROFESSIONAL EXPERIENCE 
Clinical Pharmacy Resident 
Department of Pharmacy Practice 
University of Utah Medical Center 
August 1981 - June 1983 
Responsibilities: Clinical Rotations (medical team member, daily 
patient care rounds, monitoring patient therapy, performing medi-
cation histories, providing pharmacokinetic and drug therapy 
selection, teaching inservices, and pharmacy rounds with first 
year Pharm.D. candidates and undergraduate pharmacy students) 
Night Call (drug information service, toxicology information, 
cardiac arrest team member, and patient care responsibility for 
the University of Utah Poison Control Center) 
Clinical Pharmacy Seminars (to faculty members and hospital 
pharmacists at the University of Utah) 
Committee Meetings (Institutional Review Board, Pharmacy and 
Therapeutics Committee) 
Research (see Research in Progress) 
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PROFESSIONAL EXPERIENCE (continued) 
Registered Pharmacist 
Thrift Drug Company 
Wynnewood, PA 
January 1981 - May 1981 
Responsibilities: Compounding and dispensing of medications, 
patient counseling, maintaining patient profiles, and pharmacy 
management 
Pharmacy Intern 
Thrift Drug Company 
King of Prussia, PA 
May 1978 - December 1980 
Responsibilities: Compounding and dispensing of medications under 
the supervision of a registered pharmacist 
LICENSURE 
Utah - September 1981 - #03512-1701-6 
Pennsylvania - March 1981 - //031511-L 
RESEARCH AND OTHER CREATIVE WORK 
Reviews 
Gonzalez ER: Piperacillin - A semisynthetic penicillin with en-
hanced antipseudomonas activity is admitted to the formulary. 
Drugs in Patient Care 5 (2):5-6, 1982. 
Research In Progress 
Principal Investigator: A Comparative Analysis of Plasma Concen-
tration, Arrhythmia Response, and QRS Complex and QT Interval 
Changes in Patients Requiring Quinidine Therapy. Thomas Caine, 
M.D., and Bryan Finkle, Ph.D., February 1982-present. 
Research Assistant: A Prospective Comparison of the Incidence of 
Thrombocytopenia and/or Hypertransaminasemia in Patients Receiving 
Either Beef Lung or Porcine Intestinal Mucosal Heparin. John 
Russo Jr.j Pharm.D., George Dukes Jr., Pharm.D., Steven Sanders, 
Pharm.D,, Glenn Warden, M.D., Jeffrey Saffle, M.D., May 1982-present, 
A Study of the Pharmacokinetics, Efficacy and Safety of FK 749 
(SK&F 88373-Z) in Pediatric Infections. John Russo Jr., Pharm.D., 
Kelly D. Mutchie, Pharm.D., Manford Gooch, M.D., July 1982-present, 
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RESEARCH AND OTHER CREATIVE WORK (continued) 
Invited Presentations 
"New Agents and Therapeutics for 1982: Antianginal Agents" 
Continuing Education Program, Utah Pharmaceutical Association, Salt 
Lake City, UT, Nov. 1982. 
"Vasodilator Therapy in Chronic Congestive Heart Failure" Pharmacy 
Conference, Department of Pharmacy, LDS Hospital, Salt Lake City, 
UT, Oct. 1982. 
"Digitalis Glycosides" Nursing Staff Teaching Seminar, Coronary 
Care Unit, LDS Hospital, Salt Lake City, UT, Aug. 1982. 
"Review of Cardiac Electrophysiology and Antiarrhythmic Agents" 
Medical Intensive Care Unit-Coronary Care Unit, University of Utah 
Medical Center, Salt Lake City, UT, Aug. 1982. 
"Medications Used During Acute Medical Emergencies: Agents, Doses, 
and Administration" Medical Staff Conference, Handicapped 
Children's Center, Salt Lake City, UT, July 1982, 
"Potential Complications of Ritodrine Hydrochloride in the Manage-
ment of Preterm Labor" Department of Obstetrics and Gynecology, 
University of Utah Medical Center, Salt Lake City, UT, July 1982. 
"Narcotic Withdrawal in the Pregnant Patient: Management Potential 
Risk to the Patient and the Fetus" Nursing Conference, Department 
of Obstetrics and Gynecology, University of Utah Medical Center, 
Salt Lake City, UT, June 1982. 
"Patient Noncompliance: Why It Occurs and How It Can Be 
Minimized" Team Staffing Conference, Maternal and Infant Care 
Clinic, Utah Department of Health, Salt Lake City, UT, June 1982. 
"Calcium Channel Blocking Agents" Nursing In-Service, Medical 
Intensive Care Unit-Coronary Care Unit, Salt Lake City, UT, May 
1982. 
"Recognition and Management of Acute Adrenal Insufficiency" 
Nursing In-Service, Surgical Intensive Care Unit, University of 
Utah Medical Center, Salt Lake City, UT, Feb, 1982, 
"Pulmonary Care of the Critically 111 Patient" Pharmacologic In-
tervention" Continuing Education Lecture, American Association 
of Critical Care Nurses, Salt Lake City, UT, Jan. 1982. 
"Food-Drug Interactions" Nursing Staff Teaching Rounds, Hill Haven 
Nursing Home, S al t Lake City, UT, Sept. 1981. 
RESEARCH AND OTHER CREATIVE WORK (continued) 
Seminar Presentations 
"Abrupt Discontinuation of Antihypertensive Therapy" Clinical 
Pharmacy Seminar, College of Pharmacy, University of Utah, Salt 
Lake City, UT, April 1982, 
"The Medical Management of Psoriasis" Clinical Pharmacy Seminar, 
College of Pharmacy, University of Utah, Salt Lake City, UT, 
Jan. 1982. 
"Adriamvcin Cardiotoxicitv" Clinical Pharmacy Seminar, College of 
Pharmacy, University of Utah, Salt Lake City, UT, Sept. 1981. 
COMMUNITY ACTIVITIES 
Volunteer Registered Pharmacist 
Health Screening Center 
Scllt Xj tilcG County Aging Services 
Salt Lake City, UT 
September 1981 - January 1982 
Volunteer Registered Pharmacist 
Salt Lake County Health Fair 
Salt Lake City, UT 
March 1982 
Pharmacist In-Charge 
Hypertension Screening and Monitoring 
Community Service Program, Thrift Drug Company 
Wynnewood, PA 
June 1980 - May 1981 
Diabetic Patient Education and Counseling 
Thrift Drug Company 
Wynnewood, PA 
May 1979 - May 1981 
PROFESSIONAL SOCIETIES 
American Society of Hospital Pharmacists, September 1982 - present 
Utah Society of Hospital Pharmacists, September 1982 - present 
American Pharmaceutical Association, January 1981 - present 
Pennsylvania Pharmaceutical Association, August 1979 - August 1980 
Student American Pharmaceutical Association, August 1977 -
December 1980 
